GlassScriptPhysician profile
Joel D Phillips
NPI 1811654007
$5,568.39
in general payments reported to CMS, 2019-2025
29 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $560 · 2023: $1,130 · 2024: $1,702 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,008.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,338.47 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $824.10 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $536.19 | 2022-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $382.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $261.26 | 2024-2025 | Voquezna |
| Genzyme Corporation | $247.70 | 2022-2025 | |
| Ardelyx, INC. | $232.47 | 2023-2025 | Ibsrela |
| Celgene Corporation | $228.50 | 2022-2023 | Zeposia |
| Braintree Laboratories, INC. | $204.17 | 2022-2025 | Sutab, Suflave |
| Qol Medical, LLC | $203.31 | 2022-2025 | Sucraid, Sucraid |
| Pfizer INC. | $178.62 | 2024-2025 | |
| Gilead Sciences, INC. | $173.79 | 2023-2025 | |
| Lilly USA, LLC | $119.15 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $115.66 | 2024-2025 | Zenpep |
| Vivus LLC | $73.13 | 2025 | Pancreaze |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.35 | 2023-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $60.83 | 2023-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $57.90 | 2022-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $54.72 | 2025 | Iqirvo |
| Amgen INC. | $33.29 | 2022 | |
| Intercept Pharmaceuticals, INC. | $31.23 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $27.50 | 2022 | |
| Celltrion USA INC. | $26.62 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $22.20 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.49 | 2024 | Cyltezo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.43 | 2024 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $16.06 | 2025 | Suflave |
| E.R. Squibb & Sons, L.L.C. | $12.73 | 2022 | |
| Echosens North America, INC. | $3.21 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.